FDA
-
-
-
-
-
-
-
Vanda gets FDA approval for psychiatric drug BYSANTI
-
-
-
-
-
-
-
FDA approves Vanda's NEREUS for motion sickness prevention
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)
-
-
-
-
-
-
-
Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)
-
-
-
-
-
-
-
Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

